null Interdisciplinary Consortium Receives Grant to Develop Next-Generation Cell-Based Cancer Vaccines

June 17, 2020

Source: Saint-Gobain Life Sciences. Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers. Access to these promising therapies is limited by the high costs of manufacturing at centralized locations. Saint-Gobain Life Sciences, Kanyr Pharma Inc., the Research Institute of the McGill University Health Centre and McGill University have formed a new interdisciplinary consortium to make this technology more accessible. Read more.

Development of Optimized Culture Environments for Dendritic Cell Cancer Vaccines